Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 14, 2020
Daily News
July 14, 2020
- Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
July 14, 2020
- Nichi-Iko Execs Face Pay Cuts over Massive Recalls
July 14, 2020
- AMR Action Fund Would Help Deal with Threat While We Still Have Time: IFPMA Vice Pres.
July 14, 2020
- Keio Prof. Kenya Honda Becomes Scientific Advisor for 4BIO
July 14, 2020
- Tecentriq Fails to Improve PFS in Ovarian Cancer: Roche/Chugai
July 14, 2020
- Treakisym Filed for Triple Therapy in DLBCL
July 14, 2020
- 23 Drug Makers to Invest US$1 Billion in “AMR Action Fund” to Develop 2-4 New Antibiotics by 2030
July 14, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…